Thomas Langbein
Ismaninger Str. 22
Munich, BY 81675, Germany
Munich, BY 81675, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Shades of insulinoma one century after first extensive evaluation by Wilder and colleagues; a figurative review between light and dark.
Journal: Reviews in endocrine & metabolic disorders
Published: May 26, 2026
Impact of different PSMA PET-based eligibility criteria on outcome of [177Lu]Lu-PSMA radioligand therapy using [18F]rhPSMA-7/[18F]rhPSMA-7.3 (Flotufolastat).
Journal: EJNMMI research
Published: January 12, 2026
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.
Journal: Frontiers in endocrinology
Published: October 22, 2024
Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
Journal: International journal of molecular sciences
Published: August 31, 2023
Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 06, 2022
Prognostic Role of 68Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 26, 2022
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.
Journal: Diagnostics (Basel, Switzerland)
Published: July 18, 2022
Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection.
Journal: Toxins
Published: November 26, 2021
Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 26, 2021
18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 07, 2021
Last Updated: 09/26/2026